Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Abecma (idecabtagene vicleucel) in Earlier Lines of Therapy for Triple-Class Exposed Relapsed and Refractory Multiple Myeloma finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
At median follow-up of more than 30 months, Abecma maintained a 51% reduction in risk of disease progression or death with median PFS of 13.8 months compared with 4.4 months for standard regimensResponses were significantly improved with Abecma and continued to deepen over time with a complete response rate of 44% v.
Bristol Myers Squibb s Abecma® Becomes First CAR T Approved for Use in Earlier Lines of Therapy for Patients with Relapsed or Refractory Multiple Myeloma in Japan TOKYO,.
Bristol Myers Squibb and 2seventy bio, Inc. today announced the U.S. Food and Drug Administration’s Oncologic Drugs Advisory Committee will meet to review data supporting the supplemental.